Anti-RNF19B monoclonal antibody

Pre-made anti-RNF19B monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to RNF19B/RNF19B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1523-Ab-1/ GM-Tg-hg-IP1523-Ab-2Anti-Human RNF19B monoclonal antibodyHuman
GM-Tg-rg-IP1523-Ab-1/ GM-Tg-rg-IP1523-Ab-2Anti-Rat RNF19B monoclonal antibodyRat
GM-Tg-mg-IP1523-Ab-1/ GM-Tg-mg-IP1523-Ab-2Anti-Mouse RNF19B monoclonal antibodyMouse
GM-Tg-cynog-IP1523-Ab-1/ GM-Tg-cynog-IP1523-Ab-2Anti-Cynomolgus/ Rhesus macaque RNF19B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1523-Ab-1/ GM-Tg-felg-IP1523-Ab-2Anti-Feline RNF19B monoclonal antibodyFeline
GM-Tg-cang-IP1523-Ab-1/ GM-Tg-cang-IP1523-Ab-2Anti-Canine RNF19B monoclonal antibodyCanine
GM-Tg-bovg-IP1523-Ab-1/ GM-Tg-bovg-IP1523-Ab-2Anti-Bovine RNF19B monoclonal antibodyBovine
GM-Tg-equg-IP1523-Ab-1/ GM-Tg-equg-IP1523-Ab-2Anti-Equine RNF19B monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1523-Ab-1/ GM-Tg-hg-IP1523-Ab-2; GM-Tg-rg-IP1523-Ab-1/ GM-Tg-rg-IP1523-Ab-2;
GM-Tg-mg-IP1523-Ab-1/ GM-Tg-mg-IP1523-Ab-2; GM-Tg-cynog-IP1523-Ab-1/ GM-Tg-cynog-IP1523-Ab-2;
GM-Tg-felg-IP1523-Ab-1/ GM-Tg-felg-IP1523-Ab-2; GM-Tg-cang-IP1523-Ab-1/ GM-Tg-cang-IP1523-Ab-2;
GM-Tg-bovg-IP1523-Ab-1/ GM-Tg-bovg-IP1523-Ab-2; GM-Tg-equg-IP1523-Ab-1/ GM-Tg-equg-IP1523-Ab-2
Products NameAnti-RNF19B monoclonal antibody
Formatmab
Target NameRNF19B
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-RNF19B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1523-Ag-1Recombinant multi-species RN19B/ RNF19B/ IBRDC3 protein


    Target information

    Target IDGM-IP1523
    Target NameRNF19B
    Gene ID127544,75234,313806,710523,478146,101083280,509774,100070073
    Gene Symbol and Synonyms4930534K13Rik,4930555L03Rik,IBRDC3,NKLAM,RNF19B
    Uniprot AccessionQ6ZMZ0
    Uniprot Entry NameRN19B_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000116514
    Target ClassificationN/A

    The target: RNF19B, gene name: RNF19B, also named as IBRDC3, NKLAM. This gene encodes a multi-pass membrane protein containing two RING-type and one IBR-type zinc finger motifs. The encoded protin is an E3 ubiquitin-protein ligase that plays a role in the cytotoxic effects of natural killer (NK) cells. Alternative splicing results in multiple transcript variants. There are pseudogenes for this gene on chromosomes X and Y in a possible pseudoautosomal region. [provided by RefSeq, Jul 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.